Fujisawa Pharmaceutical of Japan and Adir et Cie, a member of France'sServier Research Group, have signed a licensing agreement whereby the former gains rights to develop, manufacture and market strontium ranelate, Servier's drug for the prevention and treatment of osteoporosis, in its home market. Strontium ranelate has been shown in Phase III clinical trials to have the dual actions of enhancing bone formation and decreasing bone resorption, which differentiates it from other products on the market, notes Fujisawa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze